Necrotizing enterocolitis: Pathophysiology, platelet-activating factor, and probiotics

Seminars in Pediatric Surgery

Volumn 22, Issue 2, 2013, Pages 88-93

  Frost, Brandy L ^a   Caplan, Michael S ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Necrotizing enterocolitis; Platelet activating factor; Prematurity; Probiotics

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; BEPAFANT; LACTOFERRIN; PROBIOTIC AGENT; RNA 16S; THROMBOCYTE ACTIVATING FACTOR; TOLL LIKE RECEPTOR 4;

ARTICLE; ARTIFICIAL MILK; BACTERIAL COLONIZATION; BIFIDOBACTERIUM; BIFIDOBACTERIUM ANIMALIS; BIFIDOBACTERIUM BIFIDUM; BIFIDOBACTERIUM BREVE; BIFIDOBACTERIUM LONGUM INFANTIS; BREAST MILK; GESTATIONAL AGE; HUMAN; INTESTINE; LACTOBACILLUS; LACTOBACILLUS ACIDOPHILUS; NECROTIZING ENTEROCOLITIS; NONHUMAN; PATHOPHYSIOLOGY; PREMATURITY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RISK FACTOR; STREPTOCOCCUS THERMOPHILUS;

BIOLOGICAL MARKERS; ENTEROCOLITIS, NECROTIZING; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; INFANT, PREMATURE, DISEASES; PLATELET ACTIVATING FACTOR; PROBIOTICS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84876714403     PISSN: 10558586     EISSN: 15329453     Source Type: Journal    
DOI: 10.1053/j.sempedsurg.2013.01.005     Document Type: Article

References (61)

1. Lotz M., Gutle D., Walther S., et al. Postnatal acquisition of endotoxin tolerance in intestinal epithelial cells. J Exp Med. 2006, 203:973-984.
2. Abreu M.T., Vora P., Faure E., et al. Decreased expression of toll-like receptor-4 and MD-2 correlates with intestinal epithelial cell protection against dysregulated proinflammatory gene expression in response to bacterial lipopolysaccharide. J Immunol. 2001, 167:1609-1616.
3. Melmed G., Thomas L.S., Lee N., et al. Human intestinal epithelial cells are broadly unresponsive to toll-like receptor 2-dependent bacterial ligands: implications for host-microbial interactions in the gut. J Immunol. 2003, 170:1406-1415.
4. Jilling T., Simon D., Lu J., et al. The roles of bacteria and TLR4 in rat and murine models of necrotizing enterocolitis. J Immunol. 2006, 177:3273-3282.
5. Gonzalez-Crussi F., Hsueh W. Experimental model of ischemic bowel necrosis. The role of platelet-activating factor and endotoxin. Am J Pathol. 1983, 112:127-135.
6. Furukawa M., Lee E.L., Johnston J.M. Platelet-activating factor-induced ischemic bowel necrosis: The effect of platelet-activating factor acetylhydrolase. Pediatr Res. 1993, 34:237-241.
7. Caplan M.S., Sun X.M., Hsueh W. Hypoxia causes ischemic bowel necrosis in rats: The role of platelet-activating factor (PAF-acether). Gastroenterology. 1990, 99:979-986.
8. Caplan M.S., Hedlund E., Adler L., et al. The platelet-activating factor receptor antagonist WEB 2170 prevents neonatal necrotizing enterocolitis in rats. J Pediatr Gastroenterol Nutr. 1997, 24:296-301.
9. Caplan M.S., Lickerman M., Adler L., et al. The role of recombinant platelet-activating factor acetylhydrolase in a neonatal rat model of necrotizing enterocolitis. Pediatr Res. 1997, 42:779-783.
10. Lu J., Pierce M., Franklin A., et al. Dual roles of endogenous platelet-activating factor acetylhydrolase in a murine model of necrotizing enterocolitis. Pediatr Res. 2010, 68:225-230.
11. Caplan M.S., Sun X.M., Hseuh W., et al. Role of platelet activating factor and tumor necrosis factor-alpha in neonatal necrotizing enterocolitis. J Pediatr. 1990, 116:960-964.
12. Amer M.D., Hedlund E., Rochester J., et al. Platelet-activating factor concentration in the stool of human newborns: Effects of enteral feeding and neonatal necrotizing enterocolitis. Biol Neonate. 2004, 85:159-166.
13. Caplan M., Hsueh W., Kelly A., et al. Acetylhydrolase increases during neonatal maturation. Prostaglandins. 1990, 39:705-714.
14. Moya F.R., Eguchi H., Zhao B., et al. Platelet-activating factor acetylhydrolase in term and preterm human milk: A preliminary report. J Pediatr Gastroenterol Nutr. 1994, 19:236-239.
15. Furukawa M., Narahara H., Yasuda K., et al. Presence of platelet-activating factor-acetylhydrolase in milk. J Lipid Res. 1993, 34:1603-1609.
16. Lucas A., Cole T.J. Breast milk and neonatal necrotising enterocolitis. Lancet. 1990, 336:1519-1523.
17. Soliman A., Michelsen K.S., Karahashi H., et al. Platelet-activating factor induces TLR4 expression in intestinal epithelial cells: Implication for the pathogenesis of necrotizing enterocolitis. PloS One. 2010, 5:e15044.
18. Harmsen H.J., Wildeboer-Veloo A.C., Raangs G.C., et al. Analysis of intestinal flora development in breast-fed and formula-fed infants by using molecular identification and detection methods. J Pediatr Gastroenterol Nutr. 2000, 30:61-67.
19. Penders J., Thijs C., Vink C., et al. Factors influencing the composition of the intestinal microbiota in early infancy. Pediatrics. 2006, 118:511-521.
20. Gronlund M.M., Lehtonen O.P., Eerola E., et al. Fecal microflora in healthy infants born by different methods of delivery: Permanent changes in intestinal flora after cesarean delivery. J Pediatr Gastroenterol Nutr. 1999, 28:19-25.
21. Palmer C., Bik E.M., DiGiulio D.B., et al. Development of the human infant intestinal microbiota. PLoS Biol. 2007, 5:e177.
22. Gewolb I.H., Schwalbe R.S., Taciak V.L., et al. Stool microflora in extremely low birthweight infants. Arch Dis Child. 1999, 80:F167-F173.
23. Wang Y., Hoenig J.D., Malin K.J., et al. 16S rRNA gene-based analysis of fecal microbiota from preterm infants with and without necrotizing enterocolitis. ISME J. 2009, 3:944-954.
24. Mshvildadze M., Neu J., Shuster J., et al. Intestinal microbial ecology in premature infants assessed with non-culture-based techniques. J Pediatr. 2010, 156:20-25.
25. Alfaleh K., Anabrees J., Bassler D., et al. Probiotics for prevention of necrotizing enterocolitis in preterm infants. Cochrane Database Syst Rev. 2011, CD005496, (Online).
26. Deshpande G., Rao S., Patole S., et al. Updated meta-analysis of probiotics for preventing necrotizing enterocolitis in preterm neonates. Pediatrics. 2010, 125:921-930.
27. Hoyos A.B. Reduced incidence of necrotizing enterocolitis associated with enteral administration of Lactobacillus acidophilus and Bifidobacterium infantis to neonates in an intensive care unit. Int J Infect Dis. 1999, 3:197-202.
28. Dani C., Biadaioli R., Bertini G., et al. Probiotics feeding in prevention of urinary tract infection, bacterial sepsis and necrotizing enterocolitis in preterm infants. A prospective double-blind study. Biol Neonate. 2002, 82:103-108.
29. Lin H.C., Su B.H., Chen A.C., et al. Oral probiotics reduce the incidence and severity of necrotizing enterocolitis in very low birth weight infants. Pediatrics. 2005, 115:1-4.
30. Lin H.C., Hsu C.H., Chen H.L., et al. Oral probiotics prevent necrotizing enterocolitis in very low birth weight preterm infants: a multicenter, randomized, controlled trial. Pediatrics. 2008, 122:693-700.
31. Bin-Nun A., Bromiker R., Wilschanski M., et al. Oral probiotics prevent necrotizing enterocolitis in very low birth weight neonates. J Pediatr. 2005, 147:192-196.
32. Samanta M., Sarkar M., Ghosh P., et al. Prophylactic probiotics for prevention of necrotizing enterocolitis in very low birth weight newborns. J Trop Pediatr. 2009, 55:128-131.
33. Braga T.D., da Silva G.A., de Lira P.I., et al. Efficacy of Bifidobacterium breve and Lactobacillus casei oral supplementation on necrotizing enterocolitis in very-low-birth-weight preterm infants: A double-blind, randomized, controlled trial. Am J Clin Nutr. 2011, 93:81-86.
34. Mihatsch W.A., Vossbeck S., Eikmanns B., et al. Effect of Bifidobacterium lactis on the incidence of nosocomial infections in very-low-birth-weight infants: A randomized controlled trial. Neonatology. 2010, 98:156-163.
35. Sari F.N., Dizdar E.A., Oguz S., et al. Oral probiotics: Lactobacillus sporogenes for prevention of necrotizing enterocolitis in very low-birth weight infants: A randomized, controlled trial. Eur J Clin Nutr. 2011, 65:434-439.
36. Manzoni P., Rinaldi M., Cattani S., et al. Bovine lactoferrin supplementation for prevention of late-onset sepsis in very low-birth-weight neonates: A randomized trial. J Am Med Assoc. 2009, 302:1421-1428.
37. Axelsson I., Jakobsson I., Lindberg T., et al. Macromolecular absorption in preterm and term infants. Acta Paediatr Scand. 1989, 78:532-537.
38. Berseth C.L. Gestational evolution of small intestine motility in preterm and term infants. J Pediatr. 1989, 115:646-651.
39. Allen A., Bell A., Mantle M., et al. The structure and physiology of gastrointestinal mucus. Adv Exp Med Biol. 1982, 144:115-133.
40. Zakostelska Z., Kverka M., Klimesova K., et al. Lysate of probiotic Lactobacillus casei DN-114 001 ameliorates colitis by strengthening the gut barrier function and changing the gut microenvironment. PloS One. 2011, 6:e27961.
41. Khailova L., Dvorak K., Arganbright K.M., et al. Bifidobacterium bifidum improves intestinal integrity in a rat model of necrotizing enterocolitis. Am J Physiol. 2009, 297:G940-G949.
42. Matsumoto M., Ishige A., Yazawa Y., et al. Promotion of intestinal peristalsis by Bifidobacterium spp. capable of hydrolysing sennosides in mice. PloS One. 2012, 7:e31700.
43. Buisine M.P., Devisme L., Savidge T.C., et al. Mucin gene expression in human embryonic and fetal intestine. Gut. 1998, 43:519-524.
44. Mack D.R., Michail S., Wei S., et al. Probiotics inhibit enteropathogenic E. coli adherence in vitro by inducing intestinal mucin gene expression. Am J Physiol. 1999, 276:G941-G950.
45. Caballero-Franco C., Keller K., De Simone C., et al. The VSL#3 probiotic formula induces mucin gene expression and secretion in colonic epithelial cells. Am J Physiol. 2007, 292:G315-G322.
46. Nanthakumar N., Meng D., Goldstein A.M., et al. The mechanism of excessive intestinal inflammation in necrotizing enterocolitis: An immature innate immune response. PloS One. 2011, 6:e17776.
47. Liu Y., Fatheree N.Y., Mangalat N., et al. Lactobacillus reuteri strains reduce incidence and severity of experimental necrotizing enterocolitis via modulation of TLR4 and NF-kappaB signaling in the intestine. Am J Physiol Gastrointest Liver Physiol. 2012, 302:G608-G617.
48. Ganguli K., Meng D., Rautava S., et al. Probiotics prevent necrotizing enterocolitis by modulating enterocyte genes that regulate innate immune-mediated inflammation. Am J Physiol Gastrointest Liver Physiol. 2013, 304:G132-G141.
49. Rachmilewitz D., Katakura K., Karmeli F., et al. Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. Gastroenterology. 2004, 126:520-528.
50. Mehta A., Rangarajan S., Borate U. A cautionary tale for probiotic use in hematopoietic SCT patients-Lactobacillus acidophilus sepsis in a patient with mantle cell lymphoma undergoing hematopoietic SCT. Bone Marrow Transplant. 2012.
51. Kochan P., Chmielarczyk A., Szymaniak L., et al. Lactobacillus rhamnosus administration causes sepsis in a cardiosurgical patient-is the time right to revise probiotic safety guidelines?. Clin Microbiol Infect. 2011, 17:1589-1592.
52. Kunz A.N., Noel J.M., Fairchok M.P. Two cases of Lactobacillus bacteremia during probiotic treatment of short gut syndrome. J Pediatr Gastroenterol Nutr. 2004, 38:457-458.
53. Ohishi A., Takahashi S., Ito Y., et al. Bifidobacterium septicemia associated with postoperative probiotic therapy in a neonate with omphalocele. J Pediatr. 2010, 156:679-681.
54. Jenke A., Ruf E.M., Hoppe T., et al. Bifidobacterium septicaemia in an extremely low-birthweight infant under probiotic therapy. Arch Dis Child. 2012, 97:F217-F218.
55. Besselink M.G., van Santvoort H.C., Buskens E., et al. Probiotic prophylaxis in predicted severe acute pancreatitis: A randomised, double-blind, placebo-controlled trial. Lancet. 2008, 371:651-659.
56. Walker W.A. Mechanisms of action of probiotics. Clin Infect Dis. 2008, 46(suppl 2):S87-S91. [discussion S144-151].
57. Kalliomaki M., Salminen S., Poussa T., et al. Probiotics during the first 7 years of life: A cumulative risk reduction of eczema in a randomized, placebo-controlled trial. J Allergy Clin Immunol. 2007, 119:1019-1021.
58. Taylor A.L., Dunstan J.A., Prescott S.L. Probiotic supplementation for the first 6 months of life fails to reduce the risk of atopic dermatitis and increases the risk of allergen sensitization in high-risk children: A randomized controlled trial. J Allergy Clin Immunol. 2007, 119:184-191.
59. Drisko J., Bischoff B., Giles C., et al. Evaluation of five probiotic products for label claims by DNA extraction and polymerase chain reaction analysis. Dig Dis Sci. 2005, 50:1113-1117.
60. Marcobal A., Underwood M.A., Mills D.A. Rapid determination of the bacterial composition of commercial probiotic products by terminal restriction fragment length polymorphism analysis. J Pediatr Gastroenterol Nutr. 2008, 46:608-611.
61. Drago L., Rodighiero V., Celeste T., et al. Microbiological evaluation of commercial probiotic products available in the USA in 2009. J Chemother. 2010, 22:373-377. [Florence, Italy].